CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients

Abstract The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years. However, cytokine release syndrome (CRS) and clinical efficacy have become the ma...

Full description

Bibliographic Details
Main Authors: Mengying Ke, Liqing Kang, Ling Wang, Shu Yang, Yajun Wang, Haiyan Liu, Chunyan Gu, Hongming Huang, Ye Yang
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:https://doi.org/10.1186/s13045-021-01101-6